

# C-19 VACCINE INFO & ACCESS (VIA)

## COUNTRY PROFILE

**Bangladesh**

Dr. Md. Asifur Rahman

(Ashar Alo Society)

August 17 2021

# Bangladesh

- **Total COVID-19 cases:** 1,386,742 (upto 11 August, 2021)
- **Current COVID-19 epidemic status:** Declining
- **3 Key Impacts of COVID-19 on PLHIV and Key Populations**
  - I. Access to Treatment has been compromised
  - II. Follow up is hampered
  - III. Economic burden

# Bangladesh

- **Names of COVID-19 Vaccines approved and available**

- I. Astrazeneca
- II. Pfizer
- III. Sinopharm
- IV. Moderna

- **Price (to government):** Approx. per dose Astrazeneca (5 US \$), Pfizer (70 US \$)
- **Price (public system):** Given to public at free of cost
- **Price (private system):** Not authorized till now
- **Locally researched and/or produced vaccines:** Bangavax (Globe Biotech Limited). Awaiting for final approval to conduct the first human trial.

Source: DGHS Website

# Bangladesh

- **Vaccine target:** 80% of population
- **1st doses administered** to 14,875,182 persons. 13 (%) 1st dose against target achieved.
- **2nd doses administered** to 4,910,618 persons. 4 (%) 2nd dose against target achieved.
- **Eligibility for vaccination:** 18+ people with NID card holder including pregnant and lactating mothers.
- **Who is being left behind:** Below 18 years population
- **Key barriers for PLHIV and key populations in accessing C-19 vaccines:**
  - I. Lack of proper knowledge
  - II. Fear about vaccination

# Bangladesh

- **Thoughts and recommendations on COVID-19 Vaccine Access and Information for PLHIV and Key Populations**
  - I. Strengthen public awareness about Covid-19 vaccination
  - II. Safe and easy access to vaccination center
  - III. Free flow of right information.
  - IV. Proper Supervision and monitoring from Govt.